猴痘疫苗接种后不良事件:荷兰与全球报告系统概览
本研究基于荷兰Lareb自发报告系统及WHO全球数据库,分析2022年猴痘疫苗接种后不良事件报告。全球数据库收到2205份报告,其中131份(5.9%)为严重反应。报告的不良事件主要为注射部位反应和全身反应,与产品说明书一致。
要点
- 荷兰报告严重结局比例1.4%(2/148),全球数据库严重反应比例5.9%(131/2205)。
- 报告的不良事件以注射部位反应和全身性反应为主,多为非严重事件。
- 荷兰与全球数据库的不良事件模式与疫苗产品说明书基本一致。
核心结论
- 猴痘疫苗接种后报告的不良事件模式与产品说明书一致,主要为注射部位反应和非严重全身反应。
研究设计与样本
- 回顾性分析荷兰药物警戒中心Lareb自发报告系统及WHO全球数据库2022年猴痘/天花免疫接种后不良事件报告。
主要发现
- 2022年全球数据库收到2205份个体病例安全报告,其中131份(5.9%)涉及严重反应。
- 两个数据库中报告的不良事件主要为注射部位反应和疫苗接种后常见的全身性反应。
临床怎么用
- 临床用药决策时可参考本研究中猴痘疫苗不良事件以注射部位反应和非严重全身反应为主的安全性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The spreading of MPox (monkeypox) virus led to a vaccination campaign in the Netherlands for individuals at high risk of infection. This overview elucidates the characteristics of the reported adverse events following immunization (AEFI) following active immunization against monkeypox and thereby provides insight on the safety profile in daily practice. METHODS: Data were collected from the spontaneous reporting system of the Netherlands Pharmacovigilance Centre Lareb. Furthermore, the global database of the World Health Organization was consulted on globally reported AEFI following smallpox or monkeypox immunization in 2022. RESULTS: Until 15 November 2022, 148 unique individual case safety reports (ICSRs) regarding monkeypox vaccination were received at Lareb. Two ICSRs reported a serious outcome (1.4%). A total of 2205 ICSRs were received in the global database in 2022, of which 131 reports (5.9%) concerned a serious reaction. Reported AEFI in both databases mainly included injection site reactions and general systemic reactions commonly observed after vaccination. CONCLUSION: The pattern of reported AEFI for monkeypox vaccines both in the Dutch and global ICSR database is generally in accordance with the manufacturer's product information and consists largely of injection site reactions and nonserious AEFI related to systemic reactogenicity.
引用
- van der Boom M, van Hunsel F. Adverse reactions following MPox (monkeypox) vaccination: An overview from the Dutch and global adverse event reporting systems. Br J Clin Pharmacol. 2023. PMID: 37344609. doi:10.1111/bcp.15830
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。